Oncology
ESR1 Resistance Is Becoming a Treatment Pathway, Not a Footnote
Peer-reviewed Phase III evERA results show giredestrant plus everolimus substantially extended progression-free survival after CDK4/6 inhibitor treatment in ER-positive, HER2-negative advanced breast cancer, with the strongest effect in ESR1-mutated disease.
CLL Just Moved a Noncovalent BTK Inhibitor Into First Line
Myeloma Pain May Need 4 Gy, Not a Treatment Odyssey
Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.
Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.
FDA Told a Promising ADC: Not Yet.
Cholangiocarcinoma Just Made FGFR2 Testing Harder to Ignore
Breast Cancer Radiation De-Escalation Has an Adherence Problem
Small-Cell Lung Cancer May Be Done Irradiating Healthy Brains
Pembrolizumab Just Lost a Head-to-Head Survival Fight
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Oncology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases